Andreas Argyrides
Stock Analyst at Oppenheimer
(4.48)
# 314
Out of 5,030 analysts
115
Total ratings
52.04%
Success rate
23.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Downgrades: Perform | $13 | $16.42 | -20.83% | 3 | Oct 10, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $82.56 | +39.29% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $4.26 | +392.96% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $15.70 | +84.71% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $1.38 | +2,291.30% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: Outperform | $6 → $8 | $3.58 | +123.46% | 1 | Sep 8, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $432.69 | +32.89% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $5.35 | +180.37% | 2 | Sep 5, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | $19 → $20 | $5.47 | +265.63% | 2 | Aug 15, 2025 | |
| HRMY Harmony Biosciences Holdings | Assumes: Outperform | $61 | $25.95 | +135.07% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $7.01 | -0.14% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.24 | +141.94% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $23.18 | -43.92% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $0.47 | +749.44% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $48.60 | +85.19% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $2.80 | +221.43% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $15 | $13.74 | +9.17% | 8 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $207.03 | -12.57% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $9.38 | +1,008.74% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $3.71 | +1,924.29% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $2.31 | +289.61% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $10.11 | +87.93% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $21.55 | +34.57% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $12.34 | +70.18% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $23.34 | +859.73% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $22.78 | +150.22% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.82 | +757.95% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.64 | +1,450.63% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $52.95 | +32.20% | 6 | Aug 1, 2023 |
Dyne Therapeutics
Oct 10, 2025
Downgrades: Perform
Price Target: $13
Current: $16.42
Upside: -20.83%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $82.56
Upside: +39.29%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $4.26
Upside: +392.96%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $15.70
Upside: +84.71%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $1.38
Upside: +2,291.30%
Savara
Sep 8, 2025
Maintains: Outperform
Price Target: $6 → $8
Current: $3.58
Upside: +123.46%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $432.69
Upside: +32.89%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $5.35
Upside: +180.37%
Abeona Therapeutics
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.47
Upside: +265.63%
Harmony Biosciences Holdings
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $25.95
Upside: +135.07%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $7.01
Upside: -0.14%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.24
Upside: +141.94%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $23.18
Upside: -43.92%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.47
Upside: +749.44%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $48.60
Upside: +85.19%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.80
Upside: +221.43%
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $13.74
Upside: +9.17%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $207.03
Upside: -12.57%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $9.38
Upside: +1,008.74%
Jun 25, 2024
Initiates: Outperform
Price Target: $75
Current: $3.71
Upside: +1,924.29%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $2.31
Upside: +289.61%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $10.11
Upside: +87.93%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $21.55
Upside: +34.57%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $12.34
Upside: +70.18%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $23.34
Upside: +859.73%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.78
Upside: +150.22%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.82
Upside: +757.95%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.64
Upside: +1,450.63%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $52.95
Upside: +32.20%